ID: 20-0152 9 8 H Keinicke et al. Hepatic gene regulation by 9:8 755–768 FGF21 in DIO mice RESEARCH FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation Helle Keinicke1, Gao Sun2,*, Caroline M Junker Mentzel3, Merete Fredholm4, Linu Mary John5, Birgitte Andersen5, Kirsten Raun5 and Marina Kjaergaard5 1Insulin and Device Trial Operations, Novo Nordisk A/S, Søborg, Denmark 2Pharmacology and Histopathology, Novo Nordisk A/S, China 3Department of Experimental Animal Models, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark 4Department of Veterinary Clinical and Animal Science, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark 5Global Obesity and Liver Disease Research, Novo Nordisk A/S, Måløv, Denmark Correspondence should be addressed to M Kjaergaard:
[email protected] *(G Sun is now at Pegbio Co., Ltd, Su Zhou, China) Abstract The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically Key Words worldwide and, subsequently, also the risk of developing non-alcoholic steatohepatitis f fibroblast growth factor 21 (NASH), hepatic fibrosis, cirrhosis and cancer. Today, weight loss is the only available (FGF21) treatment, but administration of fibroblast growth factor 21 (FGF21) analogues have, f non-alcoholic fatty liver disease (NAFLD) in addition to weight loss, shown improvements on liver metabolic health but the f lipid metabolism mechanisms behind are not entirely clear. The aim of this study was to investigate the f glucose metabolism hepatic metabolic profile in response to FGF21 treatment. Diet-induced obese (DIO) f inflammation mice were treated with s.c. administration of FGF21 or subjected to caloric restriction by switching from high fat diet (HFD) to chow to induce 20% weight loss and changes were compared to vehicle dosed DIO mice.